Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure

Journal of Thoracic and Cardiovascular Surgery

Volumn 123, Issue 6, 2002, Pages 1101-1113

  Leotta, Eros ^a   Patejunas, Gerald ^a   Murphy, Glenn ^a   Szokol, Joseph ^a   McGregor, Leslie ^a   Carbray, JoAnn ^a   Hamawy, Adam ^a   Winchester, David ^a   Hackett, Neil ^b   Crystal, Ronald ^b   Rosengart, Todd ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; GENE THERAPY; GENE TRANSFER; HEART FUNCTION; HEART PACING; HEART PERFORMANCE; MALE; NONHUMAN; PRIORITY JOURNAL; THORACOTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0036622139     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.121044     Document Type: Article

References (36)

1. Tavazzi L. Epidemiologic burden of heart failure. Heart. 1998; 79(suppl 2):56-9.
2. Massie BM, Parker M. Congestive heart failure: current controversies and future prospective. Am J Cardiol. 1990;66:429-30.
3. Gillum RF. Epidemiology of heart failure in the United States. Heart J. 1993;126:1042-7.
4. Brown TA. Hibernating myocardium. Am J Crit Care. 2001;10:84-91.
5. Rinaldi CA, Hall RJ. Myocardial stunning and hibernation in clinical practice. Int J Clin Pract. 2000;54:659-64.
6. Wilson JM. Reversible congestive heart failure caused by myocardial hibernation. Tex Heart Inst J. 1999;26:19-27.
7. Thomas, KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996;271:603-6.
8. Mack CA, Patel SR, Schwarz EA, et al. Biological bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 1998;115:168-77.
9. Lee L, Patel S, Hackett N. et al. Focal angiogenic therapy using intramyocardial delivery of an adenovirus vector coding for endothelial growth factor 121. Ann Thorac Surg. 2000;69:14-24.
10. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996;2:534-9.
11. Tanaka E, Hattan N, Ando K, et al. Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits. J Thorac Cardiovasc Surg. 2000;120:720-8.
12. Yang RH, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol. 1995;27:838-44.
13. Chow E, Woodard J, Farrar D. Rapid ventricular pacing in pigs: an experimental model of congestive heart failure. Am J Physiol. 1990; 258:H1603-5.
14. Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Circulation. 1995;92:2306-17.
15. Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to airway epithelium. Cell. 1992;68:143-55.
16. Konstadt SN, Thys d, Mindich BP, et al. Validation of quantitative intraoperative transesophageal echocardiography. Anesthesiology. 1986;65:418-21.
17. Gorman JH 3rd, Gupta KB, Streicher JT, Gorman RC, Jackson BM, Ratcliffe MB, et al. Dynamic three-dimensional imaging of the mitral valve and left ventricle by rapid sonomicrometry array localization. J Thorac Cardiovasc Surg. 1996;112:712-26.
18. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study research Group. N Engl J Med. 1991;325:1468-75.
19. Rosengart T, Patel SR, Crystal RG. Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovasc Risk. 1999;8:534-9.
20. Lazarous DF, Shou M, Scheinowitz M, et al. Comparative effects of basic fibroblastic growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996;94:1074-82.
21. Banai S, Jaklitsch MT, Shou M, et al. Angiogenesis-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994;89:2183-9.
22. Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 1996;270:H17901-802.
23. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999;100:468-74.
24. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999;230: 466-70.
25. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG. Regional angiogenesis induced in non-ischemic tissue by an adenovirus vector expressing vascular endothelial growth factor. Hum Gene Ther. 1997;8:215-27.
26. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF 165 as sole therapy for myocardial ischemia. Circulation. 1998;98:2800-4.
27. Laham RJ, Selke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo controlled trial. Circulation. 1999;100:1865-71.
28. Schumacher B, Pecher P, vonSpecht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary artery disease. Circulation. 1998;97:645-50.
29. Udelson JE, Dilsizian V, Laham RJ, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation. 2000; 102:1605-10.
30. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation. 2000; 101:118-21.
31. McKirnan MD, Guo X, Waldman L, et al. Intracoronary gene transfer of fibroblast growth factor-4 increases regional contractile function and responsiveness to adrenergic stimulation in heart failure. Card Vasc Regen. 2000;1:11-21.
32. Magovern CJ, Mack CA, Zhang J, et al. Direct in vivo gene transfer to canine myocardium using a replication deficient adenovirus vector. Ann Thorac Surg. 1996;62:425-33.
33. Safi J, DiPaula A, Riccioni T, et al. Adenovirus-mediated acidic fibroblastic growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart. Microvasc Res. 1999;58:238-49.
34. Vogt Am, Kubler W. Heart failure; is there an energy deficit contributing to contractile dysfunction? Basic Res Cardiol. 1998;93:1-10.
35. Roth DA, Urasawa K, Helmer GA, Hammond KH. Downregulation of cardiac guanosine 5′-triphosphate-binding proteins in right atrium and left ventricle in pacing-induced congestive heart failure. J Clin Invest. 1993;91:939-49.
36. Marzo KP, Frey MJ, Wilson JR, et al. β-Adrenergic receptor-G protein adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. Circ Res. 1991;69:1546-56.